Back to Search
Start Over
Prophylactic nimodipine treatment and improvement in hearing outcome after vestibular schwannoma surgery: a combined analysis of a randomized, multicenter, Phase III trial and its pilot study
- Source :
- Journal of Neurosurgery. 127:1376-1383
- Publication Year :
- 2017
- Publisher :
- Journal of Neurosurgery Publishing Group (JNSPG), 2017.
-
Abstract
- OBJECTIVEIn clinical routines, neuroprotective strategies in neurosurgical interventions are still missing. A pilot study (n = 30) and an analogously performed Phase III trial (n = 112) pointed to a beneficial effect of prophylactic nimodipine and hydroxyethyl starch (HES) in vestibular schwannoma (VS) surgery. Considering the small sample size, the data from both studies were pooled.METHODSThe patients in both investigator-initiated studies were assigned to 2 groups. The treatment group (n = 70) received parenteral nimodipine (1–2 mg/hour) and HES (hematocrit 30%–35%) from the day before surgery until the 7th postoperative day. The control group (n = 72) was not treated prophylactically. Facial and cochlear nerve functions were documented preoperatively, during the inpatient care, and 1 year after surgery.RESULTSPooled raw data were analyzed retrospectively. Intent-to-treat analysis revealed a significantly lower risk for hearing loss (Class D) 12 months after surgery in the treatment group compared with the control group (OR 0.46, 95% CI 0.22–0.97; p = 0.04). After exclusion of patients with preoperative Class D hearing, this effect was more pronounced (OR 0.38, 95% CI 0.17–0.83; p = 0.016). Logistic regression analysis adjusted for tumor size showed a 4 times lower risk for hearing loss in the treatment group compared with the control group (OR 0.25, 95% CI 0.09–0.63; p = 0.003). Facial nerve function was not significantly improved with treatment. Apart from dose-dependent hypotension (p < 0.001), the study medication was well tolerated.CONCLUSIONSProphylactic nimodipine is safe and may be recommended in VS surgery to preserve hearing. Prophylactic neuroprotective treatment in surgeries in which nerves are at risk seems to be a novel and promising concept.Clinical trial registration no.: DRKS 00000328 (https://drks-neu.uniklinik-freiburg.de/drks_web/)
- Subjects :
- Adult
Male
medicine.medical_specialty
Hearing loss
Pilot Projects
Hematocrit
Hydroxyethyl starch
Lower risk
Neurosurgical Procedures
03 medical and health sciences
0302 clinical medicine
Hearing
Recurrent laryngeal nerve
Humans
Medicine
ddc:610
Hearing Loss
030223 otorhinolaryngology
Nimodipine
Retrospective Studies
medicine.diagnostic_test
business.industry
Hearing Tests
Neuroma, Acoustic
General Medicine
Middle Aged
Facial nerve
3. Good health
Surgery
Clinical trial
Neuroprotective Agents
Treatment Outcome
Anesthesia
Female
medicine.symptom
business
030217 neurology & neurosurgery
medicine.drug
Subjects
Details
- ISSN :
- 19330693 and 00223085
- Volume :
- 127
- Database :
- OpenAIRE
- Journal :
- Journal of Neurosurgery
- Accession number :
- edsair.doi.dedup.....3c89463e0f44eee2cb0f44c1b0d17874
- Full Text :
- https://doi.org/10.3171/2016.8.jns16626